| Yuan, Ying |
NCT05362617: mFOLXOX6 Versus FOLFIRI for Colorectal Patients Recurrence After Oxaplatin Based Adjuvant Chemotherapy |
|
|
| Recruiting | 3 | 328 | RoW | FOLFIRI | Second Affiliated Hospital, School of Medicine, Zhejiang University | Metastatic Colorectal Cancer | 12/22 | 12/23 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 12/24 | 07/25 | | |
NCT05171660: Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer |
|
|
| Recruiting | 3 | 436 | RoW | Sintilimab Injection, bevacizumab, Oxaliplatin, Capecitabine, Control Test, XELOX + Bevacizumab | Second Affiliated Hospital, School of Medicine, Zhejiang University | Colorectal Cancer Stage IV | 12/24 | 06/25 | | |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
| Recruiting | 3 | 306 | RoW | Chidamide, Cladribine, Gemcitabine, Busulfan, Carmustine, Etoposide, Cytarabine, Melphalan, Autologous hematopoietic stem cell transplant | Sichuan University | Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell | 12/25 | 12/25 | | |
NCT05180734: PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer |
|
|
| Recruiting | 3 | 680 | RoW | JS001/Placebo, Postoperative Adjuvant Chemotherapy, JS001/placebo combine with Postoperative Adjuvant Chemotherapy | Shanghai Junshi Bioscience Co., Ltd. | Gastric or Esophagogastric Junction Adenocarcinoma | 03/26 | 07/28 | | |
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer |
|
|
| Recruiting | 3 | 711 | Europe, Canada, Japan, US, RoW | Dostarlimab, CAPEOX, FOLFOX | GlaxoSmithKline | Colonic Neoplasms, Neoplasms, Colon | 12/28 | 12/30 | | |
NCT05409417: Exploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status |
|
|
| Recruiting | 2/3 | 40 | RoW | Experimental drug, Tilelizumab combined with chemotherapy | Second Affiliated Hospital, School of Medicine, Zhejiang University | Colorectal Cancer, Liver Metastases | 02/24 | 09/24 | | |
BEVTOR, NCT04527068: QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer |
|
|
| Not yet recruiting | 2 | 50 | RoW | Bevacizumab, QL1101, Tripleitriumab, JS001 | Second Affiliated Hospital, School of Medicine, Zhejiang University, Qilu Pharmaceutical Co., Ltd., Shanghai Junshi Bioscience Co., Ltd. | Refractory Metastatic Colorectal Cancer, pMMR, MSS | 09/21 | 02/22 | | |
BBCAPX-II, NCT04194359: Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer |
|
|
| Active, not recruiting | 2 | 25 | RoW | Sintilimab (IBI308)+bevacizumab+oxaliplatin+capecitabine | Second Affiliated Hospital, School of Medicine, Zhejiang University | Metastatic Colorectal Cancer, RAS Mutation, Microsatellite Stable | 11/22 | 12/23 | | |
| Recruiting | 2 | 50 | RoW | Raltitrexed combined with oxaplatin, Sai Wei Jian | Second Affiliated Hospital, School of Medicine, Zhejiang University | Cholangioadenoma | 12/22 | 12/23 | | |
NCT04733963: Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 112 | RoW | Fruquintinib Plus Capecitabine, Bevacizumab Plus Capecitabine | Second Affiliated Hospital, School of Medicine, Zhejiang University | Colorectal Cancer | 01/23 | 02/23 | | |
NCT05160896: SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 90 | RoW | Raltitrexed, Sai Wei Jian, Irinotecan, CPT-11, Bevacizumab, Avastin, Cetuximab, ERBITUX | Second Affiliated Hospital, School of Medicine, Zhejiang University | Advanced Metastatic Colorectal Cancer | 06/23 | 06/23 | | |
NCT06134765: Bemalenograstim Alfa for the Prevention in Patients With Colorectal Cancer/Pancreatic Cancer |
|
|
| Not yet recruiting | 2 | 89 | RoW | Bemalenograstim alfa, F-627 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Colorectal Cancer, Pancreatic Cancer | 10/24 | 03/25 | | |
NCT05785325: RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal Cancer |
|
|
| Recruiting | 2 | 30 | RoW | RC48-ADC plus Bevacizumab | Second Affiliated Hospital, School of Medicine, Zhejiang University | Colorectal Cancer | 12/23 | 12/24 | | |
NCT05894837: Serplulimab+Regorafenib +Hepatic Artery Bicarbonate Infusion in Patients With Colorectal Cancer and Liver Metastases |
|
|
| Not yet recruiting | 2 | 30 | RoW | Serplulimab+Regorafenib, Hepatic Artery Bicarbonate Infusion | Second Affiliated Hospital, School of Medicine, Zhejiang University | Colorectal Cancer, Liver Metastases | 06/24 | 06/25 | | |
NCT05555901: The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 116 | RoW | Fruquintinib+ chemotherapy, Bevacizumab+ chemotherapy | Fudan University | Metastatic Colorectal Cancer | 09/25 | 09/25 | | |
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 320 | RoW | TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab | Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb | Advanced Cancer | 02/25 | 05/25 | | |
NCT06214143: A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 68 | RoW | T3011 high dose, T3011 middle dose, T3011 low dose | Shanghai Pharmaceuticals Holding Co., Ltd | Advanced Solid Tumors | 12/25 | 05/26 | | |
NCT05260385: To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors |
|
|
| Recruiting | 1/2 | 133 | RoW | KC1036 | Beijing Konruns Pharmaceutical Co., Ltd. | Digestive System Tumors | 10/25 | 12/25 | | |
NCT05338957: A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors. |
|
|
| Recruiting | 1/2 | 30 | RoW | MRG002+HX008 | Shanghai Miracogen Inc. | Advanced Malignant Solid Tumors | 06/24 | 12/24 | | |
| Recruiting | 1 | 60 | RoW | SG1906 | Hangzhou Sumgen Biotech Co., Ltd. | Locally Advanced Unresectable or Metastatic Solid Tumors | 02/25 | 08/25 | | |
NCT05501912: A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors |
|
|
| Recruiting | 1 | 72 | RoW | ABM-1310 | ABM Therapeutics Shanghai Company Limited | Advanced Solid Tumor, BRAF V600 Mutation | 08/25 | 08/25 | | |
NCT04819516: Study of the Safety and Effectiveness of HIFU Combined With REGOTORI for Metastatic Colorectal Cancer |
|
|
| Recruiting | 1 | 10 | RoW | high-intensity focused ultrasound therapy, Toripalimab, Regorafenib | Second Affiliated Hospital, School of Medicine, Zhejiang University | Colorectal Cancer | 12/25 | 12/25 | | |
NCT06043466: A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1 | 30 | RoW | CEA-targeted CAR-T cells | Chongqing Precision Biotech Co., Ltd, Zhejiang University | Colorectal Cancer, Esophagus Cancer, Gastric Cancer, Pancreas Cancer, Non-small Cell Lung Cancer, Breast Cancer, Bile Duct Cancer | 12/26 | 12/27 | | |
INSPPIRE 2, NCT06651580: Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, Study |
|
|
| Recruiting | N/A | 1600 | Canada, US, RoW | Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Chronic Pancreatitis, Exocrine Pancreas Carcinoma, Recurrent Acute Pancreatitis | 02/27 | 02/27 | | |
NCT03958435: Real-world Retrospective Data Analysis of Adjuvant Therapy for Patients With Stage II-III Colon Cancer After Radical Surgery |
|
|
| Recruiting | N/A | 20000 | RoW | | Second Affiliated Hospital, School of Medicine, Zhejiang University | Stage II Colon Cancer, Stage III Colon Cancer, Adjuvant Therapy | 10/22 | 12/23 | | |
NCT04961125: Multicenter Study on the Pathogenic Germline Gene Variants of Colorectal Polyposis in China |
|
|
| Recruiting | N/A | 200 | RoW | germline variants | Second Affiliated Hospital, School of Medicine, Zhejiang University | Colorectal Polyposis | 12/22 | 12/24 | | |
NCT06101030: Comparing Use of Incentive Spirometry with and Without Reminder |
|
|
| Recruiting | N/A | 500 | US | Signal On | Tidal Medical Technologies | Post Operative | 03/25 | 07/25 | | |
SUMMIT, NCT03433274: Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation |
|
|
| Recruiting | N/A | 958 | Canada, US | Tendyne Mitral Valve System, MitraClip System | Abbott Medical Devices | Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases, Valve Disease, Heart, Heart Valve Diseases, Functional Mitral Regurgitation, Degenerative Mitral Valve Disease | 05/24 | 06/28 | | |
ICE-AFIB, NCT03732794: AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment |
|
|
| Active, not recruiting | N/A | 150 | US | AtriCure CryoICE & AtriClip LAA Exclusion | AtriCure, Inc. | Atrial Fibrillation (AF), Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation | 06/24 | 06/26 | | |
NCT03460769: Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT) |
|
|
| Recruiting | N/A | 600 | US | Data Management and Monitoring | M.D. Anderson Cancer Center, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Pancreatic Cancer, Chronic Pancreatitis, Diabetes Mellitus Type 3c | 06/25 | 06/25 | | |
| FANG, XUEFENG |
NCT05171660: Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer |
|
|
| Recruiting | 3 | 436 | RoW | Sintilimab Injection, bevacizumab, Oxaliplatin, Capecitabine, Control Test, XELOX + Bevacizumab | Second Affiliated Hospital, School of Medicine, Zhejiang University | Colorectal Cancer Stage IV | 12/24 | 06/25 | | |
BBCAPX-II, NCT04194359: Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer |
|
|
| Active, not recruiting | 2 | 25 | RoW | Sintilimab (IBI308)+bevacizumab+oxaliplatin+capecitabine | Second Affiliated Hospital, School of Medicine, Zhejiang University | Metastatic Colorectal Cancer, RAS Mutation, Microsatellite Stable | 11/22 | 12/23 | | |
